HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current HIV/AIDS Reports

• Publication date

  2014-07-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11904-014-0217-9PMID 24996617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011.

  2014cited by this paper
• All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C

  2014cited by this paper
• Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

  2014cited by this paper
• O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY

  2014cited by this paper
• Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

  2014cited by this paper
• Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals

  2014cited by this paper
• Treating HCV in HIV 2013: on the cusp of change

  2014cited by this paper
• Multiple hepatitis C virus (HCV) reinfections in HIV‐positive men who have sex with men: no influence of HCV genotype switch or interleukin‐28B genotype on spontaneous clearance

  2014cited by this paper
• P1234 SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION

  2014cited by this paper
• Virological response rates for telaprevir‐based hepatitis C triple therapy in patients with and without HIV coinfection

  2014cited by this paper
• Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM

  2013cited by this paper
• Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV

  2013cited by this paper
• Rates and predictors of response to anti‐viral treatment for hepatitis C virus in HIV/HCV co‐infection in a nationwide study of 619 patients

  2013cited by this paper
• svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

  2013cited by this paper
• Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

  2012cited by this paper
• All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection.

  2012cited by this paper
• Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

  2012cited by this paper
• The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007

  2011cited by this paper
• Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM

  2011cited by this paper
• A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

  2011cited by this paper
• Management of hepatocellular carcinoma: An update

  2011cited by this paper
• Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009.

  2010cited by this paper
• Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

  2010cited by this paper
• Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

  2010cited by this paper
• Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic

  2009cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009influential reference
• Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection

  2008cited by this paper
• Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

  2007cited by this paper
• Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial

  2007cited by this paper
• Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker

  2007cited by this paper
• Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

  2006cited by this paper
• Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study.

  2005cited by this paper
• Euro Surveillance : Bulletin Européen sur les Maladies Transmissibles

  2005cited by this paper
• Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.

  2005cited by this paper
• CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Metaanalysis of 3 Vanguard Studies

  2004cited by this paper
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

  2004cited by this paper
• Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

  2004cited by this paper
• Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

  2004cited by this paper
• Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper

• Return of other respiratory viruses despite the disappearance of influenza during COVID-19 control measures in Singapore

  2021cites this paper
• Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients

  2017cites this paper
• Patient‐reported outcomes in patients co‐infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL‐5 study

  2017cites this paper
• Lipid Management in Human Immunodeficiency Virus.

  2016cites this paper
• New findings in HCV genotype distribution in selected West European, Russian and Israeli regions.

  2016cites this paper
• A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients

  2015cites this paper
• Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.

  2015cites this paper
• Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection

  2015cites this paper
• Hepatitis C virus: Virology, diagnosis and treatment.

  2015cites this paper
• Epidemiology and Mechanism of Carcinogenesis of the Retrovirus HIV

  2015cites this paper
• Treatment of Hepatitis C Virus in HIV/ HCV Co-Infection

  2015cites this paper
• Natural history and treatment of Hepatitis C/HIV coinfection: is it time to change paradigms?

  2015cites this paper
• Management of lipid disorders in patients living with HIV

  2015cites this paper
• Lipid management in human immunodeficiency virus.

  2015cites this paper